Remus Pharmaceuticals Limited announced the approval from its Board during a meeting on June 20, 2025, to incorporate a new subsidiary named Espee Global Clinical Trial Services Private Limited, aimed at providing clinical trial services, with an authorized share capital of ₹1 crore.